A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal Cancer

C. Gambacorti-Passerini, J. A. Hank, M. R. Albertini, A. A. Borchert, K. H. Moore, J. H. Schiller, R. Bechhofer, E. C. Borden, B. Storer, P. M. Sondel

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Nine patients with metastatic renal cell carcinoma were entered into a pilot protocol including a 4-week regimen utilizing human recombinant interleukin-2 (IL-2) and in vitro lymphokine-activated killer (LAK) cells. The regimen included 2 weeks (4 days of treatment and 3 days of rest/week) of continuous-infusion (c.i.) IL-2 at 3 × 106U/m2/day, followed by two leukaphereses. LAK cells were cultured in vitro for 48 to 72 h and administered as a single infusion, followed by 9 days of bolus i.v. injections of 106U IL-2/m2/dose, given every 8 hours (t.i.d.). The average (\pmSD) number of LAK cells infused per patient was 7.2 × 1010(\pm3.5 × 1010). One patient showed >50% shrinkage of tumor (lung + renal bed recurrence). Toxicity was similar to that encountered in other studies using similar IL-2 doses and LAK cells and consisted of fever, hypotension, fluid retention, and reversible renal insufficiency. These results indicate that the 2 weeks of IL-2 c.i. provided conditions enabling the harvest of large quantities of mononuclear cells from the peripheral blood of patients; this could be useful for future trials requiring the use of in vitro activated lymphocytes. Nevertheless, these pilot data suggest that this regimen of prolonged t.i.d. IL-2 administration after the LAK infusion does not seem to generate any improvement in antitumor effects from those obtained using other LAK + IL-2 regimens.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Immunotherapy
Volume13
Issue number1
DOIs
StatePublished - Jan 1993

Keywords

  • Continuous infusion
  • Immunotherapy
  • Interleukin-2
  • Lymphokine-activated killer cells
  • Renal cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal Cancer'. Together they form a unique fingerprint.

  • Cite this

    Gambacorti-Passerini, C., Hank, J. A., Albertini, M. R., Borchert, A. A., Moore, K. H., Schiller, J. H., Bechhofer, R., Borden, E. C., Storer, B., & Sondel, P. M. (1993). A Pilot Phase II Trial of Continuous-Infusion Interleukin-2 Followed by Lymphokine-Activated Killer Cell Therapy and Bolus-Infusion Interleukin-2 in Renal Cancer. Journal of Immunotherapy, 13(1), 43-48. https://doi.org/10.1097/00002371-199301000-00006